Atlantic Coastal Acquisition Corp. II (ACAB)
$
5.77
Key metrics
Financial statements
Free cash flow per share
-0.5077
Market cap
46.4 Million
Price to sales ratio
0
Debt to equity
-0.2407
Current ratio
0.0380
Income quality
2.8803
Average inventory
0
ROE
0.8868
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in mobility sector. Atlantic Coastal Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.
As of 2024-11-12, Atlantic Coastal Acquisition Corp. II's market cap is $46,398,128, based on 8,041,270 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Atlantic Coastal Acquisition Corp. II has a Lower Market-Cap, indicating a difference in performance.
To buy Atlantic Coastal Acquisition Corp. II (ACAB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACAB. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $0 | EPS: $0.15 | Growth: 650%.
Visit https://www.atlanticcoastalacquisition.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $13 (2024-11-06) | All-time low: $5.75 (2024-11-12).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
8 months ago
NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Atlantic Coastal Acquisition Corp. II (Nasdaq: ACAB ), relating to its proposed merger with Abpro Merger Sub Corp. Under the terms of the agreement, each share of Abpro common stock will be converted into the right to receive 2.06 shares of Atlantic Coastal common stock.
prnewswire.com
a year ago
NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company's securities on Nasdaq.
prnewswire.com
2 years ago
NEW YORK , Oct. 18, 2023 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition corporation, announced that Atlantic Coastal Acquisition Management II LLC, the Company's initial public offering sponsor (the "Sponsor"), has deposited $80,000 into the Company's trust account (the "Trust Account) in order to extend the period of time that the Company has to complete a business combination for an additional one (1) month period, from October 19, 2023 to November 19, 2023. In exchange for the Sponsor's additional contribution to the Trust Account, the Company issued a convertible promissory note to the Sponsor in an aggregate principal amount of $80,000.
businesswire.com
2 years ago
WOBURN, Mass. & NEW YORK--(BUSINESS WIRE)--Abpro Corporation (“Abpro”), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB), a special purpose acquisition corporation (“Atlantic Costal”), today announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023. The transaction is expec.
seekingalpha.com
3 years ago
Atlantic Coastal Acquisition Corp. II raised $300 million in an IPO in January 2022.
See all news